Novo Nordisk (NVO) Chief Scientific Officer Martin Holst Lange said on Tuesday at the European Association for the Study of Diabetes conference in Vienna that the company plans to seek U.S. regulatory approval for a high-dose version of its weight-loss shot Wegovy, reported Bloomberg’s Naomi Kresge. High-dose Wegovy offers the same weight-loss potential as Eli Lilly’s (LLY) Zepbound, giving patients another option, Holst Lange is quoted as having said. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for Food and Drug Administration approval, he noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk upgraded to Buy from Neutral at Rothschild & Co Redburn
- Novo Nordisk announced results from INFORM survey on semaglutide
- Novo Nordisk Stock (NVO) Rises After Triple-Dose Trial Hits 19% Weight Loss
- Novo looks to broaden options, stay competitive in weight-loss space, FT says
- Mixed options sentiment in Novo Nordisk with shares up 1.15%